Loading…
Reported covered position: See prior filing
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Ariel Grace's Law
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Ariel Grace's Law
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BAUDAX BIO, INC. (FORMERLY KNOWN AS RECRO PHARMA, INC.) via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · RA
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Recro Pharma specifically.
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · 1A
Source: Senate LDA
| NATIONAL ASSOCIATION OF VISION CARE PLANS |
| 29 |
| 2011–2017 |
| Zogenix, Inc. | 27 | 2013–2019 |
| PHYSICIAN HOSPITALS OF AMERICA | 24 | 2011–2017 |
| GILEAD SCIENCES, INC. | 23 | 2013–2018 |
| ABIOMED INC | 22 | 2011–2019 |
| GLAXOSMITHKLINE, INC. | 21 | 2011–2019 |
| CELGENE CORPORATION | 19 | 2015–2019 |
| MERCK & CO., INC. | 19 | 2015–2019 |
| GENENTECH INC | 18 | 2014–2018 |
| SANOFI US SERVICES INC | 17 | 2015–2018 |
| AAPAN | 15 | 2011–2014 |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION | 13 | 2016–2019 |
| Alnylam Pharmaceuticals, Inc. | 13 | 2016–2019 |
| MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY | 12 | 2011–2013 |
| LOCKTON MANAGEMENT, LLC | 11 | 2017–2019 |
| NEUROCRINE BIOSCIENCES, INC | 11 | 2017–2019 |
| PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 11 | 2017–2019 |
| CHELSEA THERAPEUTICS | 9 | 2012–2014 |
| EPIGENOMICS INC. | 9 | 2017–2019 |
| FLEXION THERAPEUTICS, INC. | 9 | 2017–2019 |
| PFIZER, INC. | 9 | 2016–2017 |
| RAI SERVICES COMPANY | 9 | 2017–2019 |
| AMERICAN CAREER COLLEGE | 8 | 2011–2012 |
| EGALET CORPORATION | 8 | 2016–2017 |
| PERNIX THERAPEUTICS | 8 | 2015–2016 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 7 | 2018–2019 |
| JOHNSON & JOHNSON | 6 | 2016 |
| XL HEALTH | 6 | 2011–2012 |
| AMERICAN SOCIETY OF GENE AND CELL THERAPY | 5 | 2019 |
| EDWARDS LIFESCIENCES LLC | 5 | 2018–2019 |
| ALLERGAN, INC. | 4 | 2014 |
| BAUDAX BIO, INC. (FORMERLY KNOWN AS RECRO PHARMA, INC.) | 4 | 2019 |
| Karyopharm Therapeutics Inc. | 4 | 2018–2019 |
| WALGREEN CO | 4 | 2018–2019 |
| EXECUTIVE HEALTH RESOURCES | 3 | 2012 |
| HORIZON PHARMA | 3 | 2019 |
| IMS GOVERNMENT SOLUTIONS INC | 3 | 2011 |
| NJOY, LLC | 3 | 2019 |
| PARTNERSHIP FOR AMERICA | 3 | 2011–2012 |
| REVERE AMERICA | 3 | 2011 |
| ROIVANT SCIENCES, INC. | 3 | 2017 |
| AMARIN PHARM INC. | 2 | 2019 |
| AVANIR PHARMACEUTICALS, INC. | 2 | 2018 |
| BAYER CORPORATION | 2 | 2019 |
| BLUEBIRD BIO | 2 | 2019 |
| CARDINAL HEALTH | 2 | 2018 |
| DISPOSERX, INC. | 2 | 2019 |
| IMPOSSIBLE FOODS INC. | 2 | 2019 |
| MCKENZIE & HART | 2 | 2016 |
| SOBI NORTH AMERICA | 2 | 2019 |
| THE JEL SERT COMPANY | 2 | 2019 |
| ANHEUSER-BUSCH COMPANIES | 1 | 2018 |
| DEA SCHEDULING COALITION (INFORMAL COALITION) | 1 | 2014 |
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Ariel Grace's Law
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Ariel Grace's Law
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
21st Century Cures Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
21st Century Cures Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
21st Century Cures Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
21st Century Cures Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Advancing Breakthrough Devices for Patients Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Advancing Breakthrough Devices for Patients Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Advancing Breakthrough Devices for Patients Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Advancing Breakthrough Devices for Patients Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
FDA Device Accountability Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
FDA Device Accountability Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
FDA Device Accountability Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
FDA Device Accountability Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Improving Medical Device Innovation Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Improving Medical Device Innovation Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Improving Medical Device Innovation Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Improving Medical Device Innovation Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
To repeal certain provisions of the Patient Protection and Affordable Care Act relating to the limitation on the Medicare exception to the prohibition on certain physician referrals for hospitals and to transparency reports and reporting of physician ownership or investment interests.
Client: PHYSICIAN HOSPITALS OF AMERICA · Firm: BGR GOVERNMENT AFFAIRS
Counsel and gudiance on repealing Section 6001 of PPACA; HR1159; HR1186
To repeal certain provisions of the Patient Protection and Affordable Care Act relating to the limitation on the Medicare exception to the prohibition on certain physician referrals for hospitals and to transparency reports and reporting of physician ownership or investment interests.
Client: PHYSICIAN HOSPITALS OF AMERICA · Firm: BGR GOVERNMENT AFFAIRS
Counsel and gudiance on repealing Section 6001 of PPACA; HR1159; HR1186
To repeal certain provisions of the Patient Protection and Affordable Care Act relating to the limitation on the Medicare exception to the prohibition on certain physician referrals for hospitals and to transparency reports and reporting of physician ownership or investment interests.
Client: PHYSICIAN HOSPITALS OF AMERICA · Firm: BGR GOVERNMENT AFFAIRS
Counsel and gudiance on repealing Section 6001 of PPACA; HR1159; HR1186
To repeal certain provisions of the Patient Protection and Affordable Care Act relating to the limitation on the Medicare exception to the prohibition on certain physician referrals for hospitals and to transparency reports and reporting of physician ownership or investment interests.
Client: PHYSICIAN HOSPITALS OF AMERICA · Firm: BGR GOVERNMENT AFFAIRS
Counsel and gudiance on repealing Section 6001 of PPACA; HR1159; HR1186
To repeal changes made by health care reform laws to the Medicare exception to the prohibition on certain physician referrals for hospitals.
Client: PHYSICIAN HOSPITALS OF AMERICA · Firm: BGR GOVERNMENT AFFAIRS
Counsel and gudiance on repealing Section 6001 of PPACA; HR1159; HR1186
To repeal changes made by health care reform laws to the Medicare exception to the prohibition on certain physician referrals for hospitals.
Client: PHYSICIAN HOSPITALS OF AMERICA · Firm: BGR GOVERNMENT AFFAIRS
Counsel and gudiance on repealing Section 6001 of PPACA; HR1159; HR1186
To repeal changes made by health care reform laws to the Medicare exception to the prohibition on certain physician referrals for hospitals.
Client: PHYSICIAN HOSPITALS OF AMERICA · Firm: BGR GOVERNMENT AFFAIRS
Counsel and gudiance on repealing Section 6001 of PPACA; HR1159; HR1186
To repeal changes made by health care reform laws to the Medicare exception to the prohibition on certain physician referrals for hospitals.
Client: PHYSICIAN HOSPITALS OF AMERICA · Firm: BGR GOVERNMENT AFFAIRS
Counsel and gudiance on repealing Section 6001 of PPACA; HR1159; HR1186
Temporary Payroll Tax Cut Continuation Act of 2012
Client: GLAXOSMITHKLINE, INC · Firm: BGR GOVERNMENT AFFAIRS
PDUFA; Medicare Part-D; Vaccines; Patent Reform Act ; Importation; Prevention; Implementation of health care reform; Issues pertaining to global health; HR4013; Labor-HHS appropriations
Temporary Payroll Tax Cut Continuation Act of 2012
Client: GLAXOSMITHKLINE, INC · Firm: BGR GOVERNMENT AFFAIRS
PDUFA; Medicare Part-D; Vaccines; Patent Reform Act ; Importation; Prevention; Implementation of health care reform; Issues pertaining to global health; HR4013
Temporary Payroll Tax Cut Continuation Act of 2012
Client: GLAXOSMITHKLINE, INC · Firm: BGR GOVERNMENT AFFAIRS
PDUFA; Medicare Part-D; Vaccines; Patent Reform Act ; Importation; Prevention; Implementation of health care reform; Issues pertaining to global health; HR4013
Temporary Payroll Tax Cut Continuation Act of 2012
Client: GLAXOSMITHKLINE, INC · Firm: BGR GOVERNMENT AFFAIRS
PDUFA; Medicare Part-D; Vaccines; Importation; Prevention; Implementation of health care reform; Issues pertaining to global health; HR4013; Labor-HHS appropriations; HR 8
American Taxpayer Relief Act of 2012
Client: GLAXOSMITHKLINE, INC · Firm: BGR GOVERNMENT AFFAIRS
PDUFA; Medicare Part-D; Vaccines; Importation; Prevention; Implementation of health care reform; Issues pertaining to global health; HR4013; Labor-HHS appropriations; HR 8
To repeal certain provisions of the Patient Protection and Affordable Care Act relating to the limitation on the Medicare exception to the prohibition on certain physician referrals for hospitals and to transparency reports and reporting of physician ownership or investment interests.
Client: PHYSICIAN HOSPITALS OF AMERICA · Firm: BGR GOVERNMENT AFFAIRS
Counsel and gudiance on repealing Section 6001 of PPACA; HR3630; HR1159; HR1186
To repeal changes made by health care reform laws to the Medicare exception to the prohibition on certain physician referrals for hospitals.
Client: PHYSICIAN HOSPITALS OF AMERICA · Firm: BGR GOVERNMENT AFFAIRS
Counsel and gudiance on repealing Section 6001 of PPACA; HR3630; HR1159; HR1186
Grassroots Rural and Small Community Water Systems Assistance Act of 2011
Client: ELI LILLY & CO INC · Firm: BGR GOVERNMENT AFFAIRS
Patent reform; Medicare Part-D non-interference legislation; Medicaid rebates; Follow-on biologics (H.R. 1427; H.R. 1548); implementation of health care reform
Patent reform; Medicare Part-D non-interference legislation; Medicaid rebates; Follow-on biologics (H.R. 1427; H.R. 1548); implementation of health care reform
FY 2011 Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act; Medicare Part-D; Vaccines; Patent Reform Act of 2009 (S.515, H.R. 1260); Importation; Prevention; Implementation of health care reform; Issues pertaining to global health.
FY 2011 Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act; Medicare Part-D; Vaccines; Patent Reform Act of 2009 (S.515, H.R. 1260); Importation; Prevention; Implementation of health care reform; Issues pertaining to global health.
Strategic advice and counsel on issues impacting gene and cell therapy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · 2A
Strategic advice and counsel on issues impacting gene and cell therapy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NJOY, LLC via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · 2A
Strategic guidance and counsel on regulations and legislations related to NJOY products and business interests.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
ZOGENIX, INC. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Zogenix specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide policy analysis, strategic advice and direct advocacy support to Walgreen's related to public policy priorities for the retail pharmacy industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE JEL SERT COMPANY via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Issues pertaining to regulations on food manufacturing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NJOY, LLC via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Strategic guidance and counsel on regulations and legislations related to NJOY products and business interests.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
SOBI NORTH AMERICA via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally, and/ Sobi North America specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAUDAX BIO, INC. (FORMERLY KNOWN AS RECRO PHARMA, INC.) via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Recro Pharma specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAI SERVICES COMPANY via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide monitoring, analysis, advise and support services related to legislative and administrative policies impacting the tobacco industry
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
HCR implementation; PDUFA reauthorization; Part D; patent reform
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Providing advice, counsel, and services to support the PBOAs public policy priorities, which includes the reauthorization of the Generic Drug User Fee Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Advise client on legislative and administrative policy-making related to the biopharmaceutical industry generally, and client priorities specifically. Includes raising awareness among public officials about the importance of addressing disease areas of high unmet medical need where client is working to develop and market new medicines
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Merck specifically
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOCKTON MANAGEMENT, LLC via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Strategic guidance and counsel on ACA repeal and replace
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KARYOPHARM THERAPEUTICS INC., via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide strategic advice and counsel on legislative or regulatory actions that could impact the biopharmaceutical industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IMPOSSIBLE FOODS INC. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide stratgeic guidance and counsel on potential regulations and/or legislation impacting food innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON PHARMA via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Horizon Pharma specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Strategic guidance and counsel on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS MEDICAL CARE via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Medicare reimbursement; End stage renal disease payment reforms; implementation of health care reform; third party payments; CMS payment regulations impacting vascular access clinics and ASCs
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FLEXION THERAPEUTICS, INC. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide strategic guidance and counsel on potential changes to FDA regulations
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
DISPOSERX, INC. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation on drug disposal programs.
Filing targets: Government Accountability Office (GAO)
EPIGENOMICS, INC. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Medicare coverage for colon cancer diagnostics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY & CO INC via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Patent reform; Medicare Part-D non-interference legislation; Medicaid rebates; Follow-on biologics; implementation of health care reform; PDUFA; FDA reform; Trade issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally, and/ Celgene specifically
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUEBIRD BIO via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the gene therapies, drug pricing and other issues that impact the industry generally, and bluebird bio specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide advice and strategic counsel with regard to regulations that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, 340b, FDA regulatory issues, and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Strategic advice and counsel on issues impacting gene and cell therapy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMARIN PHARM INC. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and Amarin specifically
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Advise client on legislative and administrative policy-making related to the bio-pharmaceutical industry generally, and client priorities specifically. Includes FDA and CMS related matters, as well as issues related to the development and commercialization of bio-pharmaceuticals to treat rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide strategic advice and counsel on legislative or regulatory actions that could impact the biopharmaceutical industry; DEA scheduling of FDA approved products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
FDA regulation of medical technology, reauthorization of FDA user fee programs, the Affordable Care Act, the medical device excise tax, and Medicare coverage and reimbursement for medical technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABIOMED INC via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · Q2
Provide guidance and counsel with regard to federal medical device policy and regulatory issues and reimbursement issues within Medicare program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NJOY, LLC via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · RR
Strategic guidance and counsel on regulations and legislations related to NJOY products and business interests.
THE JEL SERT COMPANY via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · RR
Issues pertaining to regulations on food manufacturing
IMPOSSIBLE FOODS INC. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · RR
Provide stratgeic guidance and counsel on potential regulations and/or legislation impacting food innovation
BLUEBIRD BIO via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · RR
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the gene therapies, drug pricing and other issues that impact the industry generally, and bluebird bio specifically.
DISPOSERX, INC. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · RR
Provide guidance and strategic counsel with regard to regulations and legislation on drug disposal programs.
AMARIN PHARM INC. via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · RR
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and Amarin specifically
SOBI NORTH AMERICA via BGR GOVERNMENT AFFAIRS
2019 · second_quarter · RR
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally, and/ Sobi North America specifically.
BAUDAX BIO, INC. (FORMERLY KNOWN AS RECRO PHARMA, INC.) via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Recro Pharma specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON PHARMA via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Horizon Pharma specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAUDAX BIO, INC. (FORMERLY KNOWN AS RECRO PHARMA, INC.) via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · RR
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Recro Pharma specifically.
RAI SERVICES COMPANY via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Provide monitoring, analysis, advise and support services related to legislative and administrative policies impacting the tobacco industry
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
HCR implementation; PDUFA reauthorization; Part D; patent reform
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Providing advice, counsel, and services to support the PBOAs public policy priorities, which includes the reauthorization of the Generic Drug User Fee Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Advise client on legislative and administrative policy-making related to the biopharmaceutical industry generally, and client priorities specifically. Includes raising awareness among public officials about the importance of addressing disease areas of high unmet medical need where client is working to develop and market new medicines
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC. via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Merck specifically
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOCKTON MANAGEMENT, LLC via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Strategic guidance and counsel on ACA repeal and replace
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KARYOPHARM THERAPEUTICS INC., via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Provide strategic advice and counsel on legislative or regulatory actions that could impact the biopharmaceutical industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Strategic guidance and counsel on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS MEDICAL CARE via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Medicare reimbursement; End stage renal disease payment reforms; implementation of health care reform; third party payments; CMS payment regulations impacting vascular access clinics and ASCs
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FLEXION THERAPEUTICS, INC. via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Provide strategic guidance and counsel on potential changes to FDA regulations
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
EPIGENOMICS, INC. via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Medicare coverage for colon cancer diagnostics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON PHARMA via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · RR
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Horizon specifically.
ELI LILLY & CO INC via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Patent reform; Medicare Part-D non-interference legislation; Medicaid rebates; Follow-on biologics; implementation of health care reform; PDUFA; FDA reform; Trade issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally, and/ Celgene specifically
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BAYER CORPORATION via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Provide lobbying support on key issues and providing intelligence and policy tracking for relevant federal policy developments
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Strategic advice and counsel on issues impacting gene and cell therapy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZOGENIX, INC. via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Zogenix specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Provide policy analysis, strategic advice and direct advocacy support to Walgreen's related to public policy priorities for the retail pharmacy industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABIOMED INC via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Provide guidance and counsel with regard to federal medical device policy and regulatory issues and reimbursement issues within Medicare program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC. via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Provide advice and strategic counsel with regard to regulations that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, 340b, FDA regulatory issues, and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Provide strategic advice and counsel on legislative or regulatory actions that could impact the biopharmaceutical industry; DEA scheduling of FDA approved products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALNYLAM PHARMACEUTICALS, INC. via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
Advise client on legislative and administrative policy-making related to the bio-pharmaceutical industry generally, and client priorities specifically. Includes FDA and CMS related matters, as well as issues related to the development and commercialization of bio-pharmaceuticals to treat rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · Q1
FDA regulation of medical technology, reauthorization of FDA user fee programs, the Affordable Care Act, the medical device excise tax, and Medicare coverage and reimbursement for medical technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAYER CORPORATION via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · RR
Provide lobbying support on key issues, provide intelligence and policy tracking of federal policy developments.
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2019 · first_quarter · RR
Strategic advice and counsel on issues impacting gene and cell therapy
KARYOPHARM THERAPEUTICS INC., via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Provide strategic advice and counsel on legislative or regulatory actions that could impact the biopharmaceutical industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KARYOPHARM THERAPEUTICS INC., via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · RR
Provide strategic advice and counsel on legislative or regulatory actions that could impact the biopharmaceutical industry
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Advise client on legislative and administrative policy-making related to the biopharmaceutical industry generally, and client priorities specifically. Includes raising awareness among public officials about the importance of addressing disease areas of high unmet medical need where client is working to develop and market new medicines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC. via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Merck specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOCKTON MANAGEMENT, LLC via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Strategic guidance and counsel on ACA repeal and replace
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biotechnology industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAI SERVICES COMPANY via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Provide monitoring, analysis, advise and support services related to legislative and administrative policies impacting the tobacco industry
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
HCR implementation; PDUFA reauthorization; Part D; patent reform
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Providing advice, counsel, and services to support the PBOAs public policy priorities, which includes the reauthorization of the Generic Drug User Fee Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Strategic guidance and counsel on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS MEDICAL CARE via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Medicare reimbursement; End stage renal disease payment reforms; implementation of health care reform; third party payments
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FLEXION THERAPEUTICS, INC. via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Provide strategic guidance and counsel on potential changes to FDA regulations
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
EPIGENOMICS, INC. via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Medicare coverage for colon cancer diagnostics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY & CO INC via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Patent reform; Medicare Part-D non-interference legislation; Medicaid rebates; Follow-on biologics; implementation of health care reform; PDUFA; FDA reform; Trade issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally, and/ Celgene specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Provide policy analysis, strategic advice and direct advocacy support to Walgreen's related to public policy priorities for the retail pharmacy industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZOGENIX, INC. via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Zogenix specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC. via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Provide advice and strategic counsel with regard to regulations that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, 340b, FDA regulatory issues, and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Advise client on legislative and administrative policy-making related to the bio-pharmaceutical industry generally, and client priorities specifically. Includes FDA and CMS related matters, as well as issues related to the development and commercialization of bio-pharmaceuticals to treat rare diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Provide strategic advice and counsel on legislative or regulatory actions that could impact the biopharmaceutical industry; DEA scheduling of FDA approved products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ABIOMED INC via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
Provide guidance and counsel with regard to federal medical device policy and regulatory issues and reimbursement issues within Medicare program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · Q4
FDA regulation of medical technology, reauthorization of FDA user fee programs, the Affordable Care Act, the medical device excise tax, and Medicare coverage and reimbursement for medical technology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2018 · fourth_quarter · RR
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry.
SANOFI US SERVICES INC via BGR GOVERNMENT AFFAIRS
2018 · third_quarter · Q3
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biotechnology industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAI SERVICES COMPANY via BGR GOVERNMENT AFFAIRS
2018 · third_quarter · Q3
Provide monitoring, analysis, advise and support services related to legislative and administrative policies impacting the tobacco industry
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE